SEC EDGARJUL 291 min read$ISRG

Brosius Mark sold $30K of ISRG

Brosius Mark (EVP & Chief Mfg and Supply Cha) sold 84 shares of INTUITIVE SURGICAL INC (ISRG) at an average of $356.60 ($344.00–$365.58) across 3 trades over 2026-07-27 to 2026-07-29 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Brosius Mark

Published Jul 29, 2026, 9:31 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jul 29, 2026, 9:35 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ISRG

Neutral

high confidence

Mentioned

$ISRG

Relevance

2/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ISRGNeutralLow

Why it matters

The newest fact is the specific open-market sale by an officer under a pre-arranged 10b5-1 plan; it does not provide new operational or financial information about ISRG.

Market read

Traders may note incremental insider selling, but the planned nature and modest dollar value suggest limited decision impact.

What to watch

The sale size is small relative to typical ISRG trading activity, and the disclosure does not include any new company-specific developments.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-29 after-hours; reflects sales executed 2026-07-27 to 2026-07-29.

Background

The article is an SEC Form 4 insider transaction disclosure for Intuitive Surgical (ISRG).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ISRGNeutralHigh confidence

Context

Form 4 shows ISRG EVP Mark Brosius sold $29,954 of shares in open-market trades under a pre-arranged 10b5-1 plan (84 shares).

Expected impact

Likely minimal near-term impact; any effect is typically absorbed as routine 10b5-1 selling.

Evidence & confidence

The filing is an insider open-market sale, explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying company-specific news (earnings, guidance, deal, or regulatory action).

Market effects

Sector

No direct read-through to medical device sector fundamentals from a small, planned insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even planned 10b5-1 sales can coincide with internal views on valuation or liquidity needs, so some traders may still treat it as mild bearish sentiment.

Key entities

issuer
ISRG
Intuitive Surgical, the company whose insider transaction is disclosed.
insider
Brosius Mark
EVP and Chief Mfg and Supply Chain officer who sold shares.
trading mechanism
10b5-1 plan
Pre-arranged plan indicating the trades were scheduled in advance.

Read at source ← All news

SEP 15

$ISRGHighAI 8/10

Intuitive receives CE mark for transvaginal use of da Vinci SP system

Intuitive Surgical (ISRG) received CE mark approval for its da Vinci SP system for transvaginal gynecological procedures in Europe, expanding its use in women's health. The system, already approved for other surgeries, allows single-incision operations, potentially improving recovery and outcomes. It is also approved in the US, Japan, and Korea.

yahoo.com2 min

SEP 14

$ISRGHigh

Intuitive announces expanded indication for da Vinci SP in Europe

Intuitive (ISRG) received CE mark approval for transvaginal gynecologic procedures using the da Vinci SP system in Europe, expanding its applications. The approval allows for less invasive options and potentially better recovery experiences. The system is already approved in the US, Japan, and Korea for various procedures.

prnewswire.com2 min

SEP 13

$GSMed

Robots Everywhere: Goldman Sachs Now Sees 6.5 Million Humanoid Robots by 2035

Goldman Sachs projects 6.5 million humanoid robots will be shipped globally by 2035, representing a $138 billion market opportunity. Companies like Tesla, TSMC, Teradyne, and NVIDIA are positioned to benefit, with some already showing significant revenue growth. A potential AI slowdown is cited as a risk to this forecast.

yahoo.com3 min

SEP 10

$IARTMedAI 8/10

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Integra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.

yahoo.com3 min

SEP 9

$ISRGMed

ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now?

Intuitive Surgical (ISRG) trades at its lowest valuation in a decade, with a forward P/E of 30.26x, below its 10-year median. Despite a 40% decline, Q2 2026 revenue grew 19% to $2.89B, and EPS rose 28%. Management maintained 2026 da Vinci procedure growth forecast at 13.5-15.5%, citing international growth but noting U.S. and China uncertainties. ISRG's product pipeline includes da Vinci 5 and Ion systems, with innovations like SP procedures up 61%. Shares lag industry and sector, down 15% in 3

theglobeandmail.com3 min

SEP 8

$ISRGHighAI 9/10

Intuitive Wins Potential $420M DLA Surgical Robot Supply IDIQ - GovCon Wire

Intuitive Surgical (ISRG) won a potential $420M contract from the Defense Logistics Agency to supply surgical robots and related equipment over five years. The contract was awarded through a competitive process and will be funded through FY 2025. Work will be performed in California.

govconwire.com1 min